Anti-Tissue Factor Antibodies and Compositions with Enhanced Effector Function
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Dec 18, 2008
app pub date -
Apr 28, 2008
filing date -
Apr 30, 2007
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
Variants of antibodies to human tissue factor are optimized for the capability to elicit effector functions produced by immune effector cells while maintaining the ability to neutralize the biological functions of tissue factor, such as the prevention of blood clotting via the extrinsic pathway, and are produced by mutations of the Fc-region of the antibody. The variants comprise A330Y, A330I, and I332E where the I332E variant may optionally further comprise a second substitution selected from A330I (in the case of the first substitution being I332E), V264I, and S239D. The variants may further be optimized for the capability to elicit effector functions produced by immune effector cells by production of the antibody variants under conditions that produce effector function enhancing glycosylation of the Fc-region.
First Claim
Family
International Classification(s)
- A61K:PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOS....
- C07H:SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTI....
- C12N:MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF
- A01K:ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; ....
- A61P:THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDI....
- C07K:PEPTIDES
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully